<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">epidemiology</journal-id><journal-title-group><journal-title xml:lang="ru">Эпидемиология и Вакцинопрофилактика</journal-title><trans-title-group xml:lang="en"><trans-title>Epidemiology and Vaccinal Prevention</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2073-3046</issn><issn pub-type="epub">2619-0494</issn><publisher><publisher-name>«Numicom» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.31631/2073-3046-2022-21-5-29-37</article-id><article-id custom-type="elpub" pub-id-type="custom">epidemiology-1672</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group></article-categories><title-group><article-title>Оценка эффективности вакцинации Спутником V от COVID-19 сотрудников ОАО «Российские железные дороги»</article-title><trans-title-group xml:lang="en"><trans-title>Evaluation of the Effectiveness of Vaccination of Russian Railways employees</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6290-6586</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Костенко</surname><given-names>Н. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Kostenko</surname><given-names>N. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Наталья Алексеевна Костенко  – кандидат медицинских наук, начальник отдела планирования и  организации медицинской помощи Центральной дирекции здравоохранения, ОАО «Российские железные дороги»; младший научный сотрудник, НИИ медицины труда имени академика Н. Ф. Измерова</p><p> </p></bio><bio xml:lang="en"><p>Natalya A. Kostenko – Cand. Sci. (Med.), Head of the Department for Planning and Organization of Medical Care of the Central Directorate of Health, JSC «Russian Railways»; Junior Research Fellow in the Izmerov Research Institute of Occupational Health</p></bio><email xlink:type="simple">KostenkoNA@dmo.org.rzd.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6831-9486</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Жидкова</surname><given-names>Е. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Jidkova</surname><given-names>E. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Елена Анатольевна Жидкова – начальник Центральной дирекции здравоохранения ОАО «Российские железные дороги»; старший преподаватель кафедры ЮНЕСКО «Здоровый образ жизни – залог успешного развития» Московского государственного медико-стоматологического университета им. А. И. Евдокимова</p></bio><bio xml:lang="en"><p>Elena A. Jiidkova – Head of the Healthcare Department of JSC «Russian Railways»; Senior Lecturer of the UNESCO Chair «Healthy lifestyle is the key to successful development» of Moscow State University of Medicine and Dentistry</p></bio><email xlink:type="simple">zhidkovaea@dmo.org.rzd.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1620-6233</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Горяев</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Goriaev</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Артем Анатольевич Горяев – заместитель начальника отдела планирования и организации медицинской помощи </p></bio><bio xml:lang="en"><p>Artem A. Goryaev  – Deputy Head of  the Department of  Planning and Organization of Medical Care of the Central Directorate of Healthcare</p></bio><email xlink:type="simple">GoryaevAA@dmo.org.rzd.ru</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0538-6577</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шаньгин</surname><given-names>И. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Shangin</surname><given-names>I. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Иван Владимирович Шаньгин  – старший инспектор по производственным вопросам отдела планирования и  организации медицинской помощи Центральной дирекции здравоохранения </p></bio><bio xml:lang="en"><p>Ivan V. Shangin – Senior Inspector for Production Issues of the Department of Planning and Organization of Medical Care of the Central Directorate of Healthcare</p></bio><email xlink:type="simple">shanginiv@dmo.org.rzd.ru</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1230-9385</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Халтурина</surname><given-names>Д. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Khaltourina</surname><given-names>D. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Дарья Андреевна Халтурина  – начальник управления профилактики факторов риска и коммуникационных технологий в здравоохранении </p></bio><bio xml:lang="en"><p>Daria A. Khaltourina – Head of Department of Risk Factors Prevention and Communication Technologies in Healthcare </p></bio><email xlink:type="simple">khaltourina@mednet.ru</email><xref ref-type="aff" rid="aff-4"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7954-7823</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Матвеев</surname><given-names>Ю. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Matveyev</surname><given-names>Y. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Юрий Николаевич Матвеев – старший лаборант научно-исследовательской лаборатории </p></bio><bio xml:lang="en"><p>Yury N. Matveev  – Senior Technician of  Research Lab</p></bio><email xlink:type="simple">yumatveyev@gmail.com</email><xref ref-type="aff" rid="aff-5"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3800-1108</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Устюжанин</surname><given-names>В. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Ustyuzhanin</surname><given-names>V. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Вадим Витальевич Устюжанин – cтажер-исследователь</p></bio><bio xml:lang="en"><p>Vadim V. Ustyuzhanin – trainee researcher</p></bio><email xlink:type="simple">gimolosttt@gmail.com</email><xref ref-type="aff" rid="aff-6"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7603-6064</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гуревич</surname><given-names>К. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Gurevich</surname><given-names>K. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Константин Георгиевич Гуревич – доктор медицинских наук, профессор, заведующий кафедрой ЮНЕСКО «Здоровый образ жизни – залог успешного развития», Московского государственного медико-стоматологического университета им. А. И. Евдокимова; ведущий научный сотрудник НИИ организации здравоохранения и медицинского менеджмента Департамента здравоохранения города Москвы</p></bio><bio xml:lang="en"><p>Konstantin G. Gurevich  – Dr. Sci. (Med.), Professor Head of  department UNESCO Chair «Healthy lifestyle is the key to successful development» of  Moscow State University of Medicine and Dentistry; Leading Researcher, Research Institute of Health Organization and Medical Management of  the Moscow City Health Department</p></bio><email xlink:type="simple">kgurevich@mail.ru</email><xref ref-type="aff" rid="aff-7"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ОАО «Российские железные дороги»; &#13;
ФГБУ «Научно-исследовательский институт медицины труда имени академика Н. Ф. Измерова»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>JSC "Russian Railways";&#13;
Federal Research Budgetary Scientific Institution "Izmerov Research Institute of Occupational Health"</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ОАО «Российские железные дороги»; &#13;
ФГБОУ ВО «Московский государственный медико-стоматологический университет им. А.И. Евдокимова» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>JSC "Russian Railways";&#13;
The Moscow State University of Medicine and Dentistry;</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>ОАО «Российские железные дороги»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>JSC "Russian Railways"</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-4"><aff xml:lang="ru"><institution>ФГБУ «Центральный научно-исследовательский институт организации и информатизации здравоохранения» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Federal Research Institute for Health Organization and Informatics of Ministry of Health of the Russian Federation</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-5"><aff xml:lang="ru"><institution>Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Moscow Regional Research and Clinical Institute</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-6"><aff xml:lang="ru"><institution>Национальный исследовательский университет «Высшая школа экономики»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>National Research University Higher School of Economics</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-7"><aff xml:lang="ru"><institution>ФГБОУ ВО «Московский государственный медико-стоматологический университет им. А.И. Евдокимова» Минздрава России;&#13;
ГБУ «Научно-исследовательский институт организации здравоохранения и медицинского менеджмента Департамента здравоохранения города Москвы»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>The Moscow State University of Medicine and Dentistry;&#13;
Research Institute of Health Organization and Medical Management of the Moscow City Health Department</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2022</year></pub-date><pub-date pub-type="epub"><day>19</day><month>11</month><year>2022</year></pub-date><volume>21</volume><issue>5</issue><fpage>29</fpage><lpage>37</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Костенко Н.А., Жидкова Е.А., Горяев А.А., Шаньгин И.В., Халтурина Д.А., Матвеев Ю.Н., Устюжанин В.В., Гуревич К.Г., 2022</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="ru">Костенко Н.А., Жидкова Е.А., Горяев А.А., Шаньгин И.В., Халтурина Д.А., Матвеев Ю.Н., Устюжанин В.В., Гуревич К.Г.</copyright-holder><copyright-holder xml:lang="en">Kostenko N.A., Jidkova E.A., Goriaev A.A., Shangin I.V., Khaltourina D.A., Matveyev Y.N., Ustyuzhanin V.V., Gurevich K.G.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.epidemvac.ru/jour/article/view/1672">https://www.epidemvac.ru/jour/article/view/1672</self-uri><abstract><sec><title>Актуальность</title><p>Актуальность. Эффективность вакцинации работающего населения от COVID-19 в российских условиях изучена недостаточно.</p></sec><sec><title>Цель</title><p>Цель. Целью исследования является оценка эффективности вакцинации Гам-КОВИД-Вак (Спутником V) среди работающего населения на примере ОАО «РЖД».</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. Исследование эффективности вакцинации Спутником V среди работников ОАО «РЖД» в период с 21 января до 31 ноября 2021 г. было проведено методом Кокс-регрессии.</p></sec><sec><title>Результаты и обсуждение</title><p>Результаты и обсуждение. С учётом социально-демографических факторов, эффективность вакцинации против COVID-19 составила для двух прививок Спутника V – 97,8% (95% ДИ 97,8–97,9%), для одной прививки Спутника V или Спутника Лайт – 91,9% (95% ДИ 91,6–92,2%), для ревакцинации Спутником V – 97,9% (95% ДИ 97,6–98,1%). Эффективность вакцинации против COVID-19 с госпитализацией составила для Спутника V – 97,5% (95% ДИ 97,1–97,9%), для одной прививки – 86,1% (95% ДИ 83,7–88,1%), для ревакцинации – 98,2% (95% ДИ 96,3–99,2%). Эффективность вакцинации двумя прививками Спутника V против COVID-19 с летальным исходом оказалась на уровне 95,2% (95% ДИ 93,1–96,6%), а одной прививки – 94,8% (95% ДИ 89–97,6%). Высокая эффективность вакцинации могла быть связана с достаточно молодым возрастным составом работников «РЖД».</p></sec><sec><title>Выводы</title><p>Выводы. Исследование показало высокую эффективность вакцинации Спутником V против COVID-19 среди работающего населения.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Relevance</title><p>Relevance. The effectiveness of vaccination of the working population against COVID-19 in the Russian background has not been studied enough.</p></sec><sec><title>Aim</title><p>Aim. To evaluate the effectiveness of vaccination of the working population with Gam-COVID-Vak (Sputnik V) in the Russian Railways as an example.</p></sec><sec><title>Materials &amp; Methods</title><p>Materials &amp; Methods.The effectiveness of vaccination with Sputnik V among employees of Russian Railways in the period from January 21 to November 31, 2021 was performed with the Cox regression method.</p></sec><sec><title>Results</title><p>Results. The effectiveness of Sputnik V against COVID-19 infection with was 97.8% (95% CI 97.8–97.9%) for two doses, 91.9% (95% CI 91.6–92.2%) for a single dose, and 97.9% (95% CI 97.6–98.1%) for revaccination, all after socio-demographic factors adjusted. The effectiveness of vaccination against COVID-19 with hospitalization was 97.5% for two doses of Sputnik V (95% CI 97.1–97.9%), 86.1% (95% CI 83.7–88.1%) for a single dose, and 98.2% (95% CI 96.3–99.2%) for revaccination. The effectiveness against lethal COVID-19 was 95.2% (95% CI 93.1–96.6%) for two doses of Sputnik V and 94.8% (95% CI 89–97.6%) for one dose. The high efficiency of vaccination could be associated with a fairly young age composition of the employees of the Russian Railways.</p></sec><sec><title>Conclusions</title><p>Conclusions. The study showed the high effectiveness of vaccination with Sputnik V against COVID-19 among the working population.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>вакцинация</kwd><kwd>COVID-19</kwd><kwd>работающие</kwd><kwd>Спутник-V</kwd><kwd>ОАО «Российские железные дороги»</kwd><kwd>наблюдательное исследование</kwd></kwd-group><kwd-group xml:lang="en"><kwd>vaccination</kwd><kwd>Covid-19</kwd><kwd>employees</kwd><kwd>Sputnik-V</kwd><kwd>JSC «Russian Railways»</kwd><kwd>observational study</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Logunov D.Y., Dolzhikova I.V., Shcheblyakov D.V., et al. Gam-COVID-Vac Vaccine Trial Group. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia // Lancet. 2021. Vol. 397, № 10275. P. 671–681. doi:10.1016/S0140-6736(21)00234-8</mixed-citation><mixed-citation xml:lang="en">Logunov DY, Dolzhikova IV, Shcheblyakov DV, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021;397:671–81. doi:10.1016/S0140-6736(21)00234-8</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">González S., Olszevicki S., Salazar M., et al. Effectiveness of the first component of Gam-COVID-Vac (Sputnik V) on reduction of SARS-CoV-2 confirmed infections, hospitalisations and mortality in patients aged 60-79: a retrospective cohort study in Argentina. EClinicalMedicine. 2021. Vol. 40. P. 101126. doi:10.1016/j.eclinm.2021.101126</mixed-citation><mixed-citation xml:lang="en">González S, Olszevicki S, Salazar M, et al. Effectiveness of the first component of Gam-COVID-Vac (Sputnik V) on reduction of SARS-CoV-2 confirmed infections, hospitalisations and mortality in patients aged 60-79: a retrospective cohort study in Argentina. EClinicalMedicine 2021; 40: 101126. doi:10.1016/j.eclinm.2021.101126</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Rearte A., Castelli J.M., Rearte R., et al. Effectiveness of rAd26-rAd5, ChAdOx1 nCoV-19, and BBIBP-CorV vaccines for risk of infection with SARS-CoV-2 and death due to COVID-19 in people older than 60 years in Argentina: a test-negative, case-control, and retrospective longitudinal study. Lancet. 2022. Vol. 399, № 10331. P. 1254–1264. doi:0.1016/S0140-6736(22)00011-3</mixed-citation><mixed-citation xml:lang="en">Rearte A, Castelli JM, Rearte R, et al. Effectiveness of rAd26-rAd5, ChAdOx1 nCoV-19, and BBIBP-CorV vaccines for risk of infection with SARS-CoV-2 and death due to COVID-19 in people older than 60 years in Argentina: a test-negative, case-control, and retrospective longitudinal study. Lancet 2022; 399: 1254–64. doi:0.1016/S0140-6736(22)00011-3</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Vokó Z., Kiss Z., Surján G., et al. Nationwide effectiveness of five SARS-CoV-2 vaccines in Hungary-the HUN-VE study // Clin. Microbiol. Infect. 2022. Vol. 28, № 3. P. 398–404. doi:10.1016/j.cmi.2021.11.011</mixed-citation><mixed-citation xml:lang="en">Vokó Z, Kiss Z, Surján G, et al. Nationwide effectiveness of five SARS-CoV-2 vaccines in Hungary-the HUN-VE study. Clin Microbiol Infect 2022;28:398–404. doi:10.1016/j.cmi.2021.11.011</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Petrović V., Vuković V., Patić A., et al. Immunogenicity of BNT162b2, BBIBP-CorV and Gam-COVID-Vac vaccines and immunity after natural SARS-CoV-2 infection-A comparative study from Novi Sad, Serbia // PLoS One. 2022. Vol. 17, № 2. P. e0263468. doi:10.1371/journal.pone.0263468</mixed-citation><mixed-citation xml:lang="en">Petrović V, Vuković V, Patić A, et al. Immunogenicity of BNT162b2, BBIBP-CorV and Gam-COVID-Vac vaccines and immunity after natural SARS-CoV-2 infection-A comparative study from Novi Sad, Serbia. PLoS One 2022; 17: e0263468. doi:10.1371/journal.pone.0263468</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Matveeva O., Ershov A. Retrospective Cohort Study of the Effectiveness of the Sputnik V and EpiVacCorona Vaccines against the SARS-CoV-2 Delta Variant in Moscow (June–July 2021). Vaccines. 2022. Vol. 10, № 7. P. 984. doi:10.3390/vaccines10070984</mixed-citation><mixed-citation xml:lang="en">Matveeva O, Ershov A. Retrospective Cohort Study of the Effectiveness of the Sputnik V and EpiVacCorona Vaccines against the SARS-CoV-2 Delta Variant in Moscow (June–July 2021). Vaccines. 2022; 10: 984. doi:10.3390/vaccines10070984</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Рыжиков А. Б., Рыжиков Е. А., Богрянцева М. П. и др. Простое слепое плацебо-контролируемое рандомизированное исследование безопасности, реактогенности и иммуногенности вакцины «ЭпиВакКорона» для профилактики COVID-19 на добровольцах в возрасте 18–60 лет (фаза I–II). Инфекция и иммунитет. 2021. Т. 11. №. 2. С. 283–296. doi:10.15789/2220-7619ASB-1699</mixed-citation><mixed-citation xml:lang="en">Ryzhikov AB, Ryzhikov ЕА, Bogryantseva MP, et al. A single blind, placebo-controlled randomized study of the safety, reactogenicity and immunogenicity of the ‘EpiVacCorona’ Vaccine for the prevention of COVID-19, in volunteers aged 18–60 years (phase I–II). Infektsiia Immun. 2021; 11: 283–96. doi:10.15789/2220-7619-ASB-1699</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Kozlovskaya L.I., Piniaeva A.N., Ignatyev G.M., et al. Long-term humoral immunogenicity, safety and protective efficacy of inactivated vaccine against COVID-19 (CoviVac) in preclinical studies // Emerg. Microbes Infect. 2021. Vol. 10, № 1. P. 1790–1806. doi:10.1080/22221751.2021.1971569</mixed-citation><mixed-citation xml:lang="en">Kozlovskaya LI, Piniaeva AN, Ignatyev GM, et al. Long-term humoral immunogenicity, safety and protective efficacy of inactivated vaccine against COVID-19 (CoviVac) in preclinical studies. Emerg Microbes Infect. 2021; 10: 1790–806. doi:10.1080/22221751.2021.1971569</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Bagrov D.V., Glukhov G.S., Moiseenko A.V., et al. Structural characterization of β-propiolactone inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) particles. Microsc. Res. Tech. 2022. Vol. 85, № 2. P. 562–569. doi:10.1002/jemt.23931</mixed-citation><mixed-citation xml:lang="en">Bagrov DV, Glukhov GS, Moiseenko AV, et al. Structural characterization of β-propiolactone inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) particles. Microsc Res Tech. 2022; 85: 562–9. doi:10.1002/jemt.23931</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Ishmukhametov A.A., Siniugina A.A., Yagovkina N.V., et al. Safety and immunogenicity of inactivated whole virion vaccine CoviVac against COVID-19: a multicenter, randomized, double-blind, placebocontrolled phase I/II clinical trial. Medrxiv. 2022. doi:10.1101/2022.02.08.22270658</mixed-citation><mixed-citation xml:lang="en">Ishmukhametov AA, Siniugina AA, Yagovkina NV, et al. Safety and immunogenicity of inactivated whole virion vaccine CoviVac against COVID-19: a multicenter, randomized, double-blind, placebocontrolled phase I/II clinical trial. bioRxiv. 2022; published online Feb 9. doi:10.1101/2022.02.08.22270658</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Korang S.K., von Rohden E., Veroniki A.A., et al. Vaccines to prevent COVID-19: A living systematic review with Trial Sequential Analysis and network meta-analysis of randomized clinical trials // PLoS One. 2022. Vol. 17, № 1. P. e0260733. doi:10.1186/s13643-020-01516-1</mixed-citation><mixed-citation xml:lang="en">Korang SK, von Rohden E, Veroniki AA, et al. Vaccines to prevent COVID-19: A living systematic review with Trial Sequential Analysis and network meta-analysis of randomized clinical trials. PLoS One. 2022; 17: e0260733. doi:10.1186/s13643-020-01516-1</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Shah S., Gui H., Chua P.E.Y., et al. Factors associated with COVID-19 vaccination intent in Singapore, Australia and Hong Kong // Vaccine. 2022. Vol. 40, № 21. P. 2949–2959. doi:10.1016/j.vaccine.2022.03.062</mixed-citation><mixed-citation xml:lang="en">Shah S, Gui H, Chua PEY, et al. Factors associated with COVID-19 vaccination intent in Singapore, Australia and Hong Kong. Vaccine. 2022; 40: 2949–59. doi:10.1016/j.vaccine.2022.03.062</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Falahi S., Kenarkoohi A. Host factors and vaccine efficacy: Implications for COVID-19 vaccines. J. Med. Virol. 2022. Vol. 94, № 4. P. 1330–1335. doi:10.1002/jmv.27485</mixed-citation><mixed-citation xml:lang="en">Falahi S, Kenarkoohi A. Host factors and vaccine efficacy: Implications for COVID-19 vaccines. J Med Virol. 2022; 94: 1330–5. doi:10.1002/jmv.27485</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Su Z., Cheshmehzangi A., McDonnell D., et al. Gender inequality and health disparity amid COVID-19 // Nurs. Outlook. 2022. Vol. 70, № 1. P. 89–95. doi:10.1016/j.outlook.2021.08.004</mixed-citation><mixed-citation xml:lang="en">Su Z, Cheshmehzangi A, McDonnell D, et al. Gender inequality and health disparity amid COVID-19. Nurs Outlook. 2022; 70: 89–95. doi:10.1016/j.outlook.2021.08.004</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Жидкова Е. А., Гутор Э. М., Вильк М. Ф. и др. Изучение позиции к здоровью и здоровому образу жизни у работников железнодорожной отрасли. Проблемы социальной гигиены, здравоохранения и истории медицины. 2021. Т. 29, № S2. С. 1350–1357. doi:10.32687/0869-866X-2021-29-s2-1350-1357</mixed-citation><mixed-citation xml:lang="en">Zhidkova EA, Gutor EM, Vilk MF, et al. The study of attitudes towards health and a healthy lifestyle among employees of the railway industry. Problems of social hygiene, health care and the history of medicine. 2021; 29:1350–7. (In Russ). doi:10.32687/0869-866X-2021-29-s2-1350-1357</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Xiao J., Cheung J.K., Wu P., et al. Temporal changes in factors associated with COVID-19 vaccine hesitancy and uptake among adults in Hong Kong: Serial cross-sectional surveys. Lancet Reg Health West Pac. 2022. Vol. 23. P. 100441. doi:10.1016/j.lanwpc.2022.100441</mixed-citation><mixed-citation xml:lang="en">Xiao J, Cheung JK, et al. Temporal changes in factors associated with COVID-19 vaccine hesitancy and uptake among adults in Hong Kong: Serial cross-sectional surveys. Lancet Reg Health West Pac. 2022; 23: 100441. doi:10.1016/j.lanwpc.2022.100441</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Жидкова Е. А., Костенко Н. А., Горяев А. А., Гуревич К. Г. Особенности заболеваемости и течения COVID-19 у сотрудников ЧУЗ ОАО «РЖД». Медицина труда и промышленная экология. 2021. Т. 61, № 8. С. 534–539. doi:10.31089/1026-9428-2021-61-8-534-539</mixed-citation><mixed-citation xml:lang="en">Zhidkova EA, Kostenko NA, Goryaev AA, Gurevich KG. Peculiarities of the incidence and course of COVID-19 among the employees of the CHUZ JSC «Russian Railways». Occupational Health and Industrial Ecology. 2021; 61:534–9. (In Russ). doi:10.31089/1026-9428-2021-61-8-534-539</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
